文献速递淋巴瘤

固定疗程epcoritamab联合R2在复发或难治性滤泡性淋巴瘤中带来良好结局

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.
PubMed 文献 · Blood · 2025-01-01

在EPCORE NHL-2研究第2臂中,108例复发/难治性滤泡性淋巴瘤患者接受固定疗程epcoritamab联合利妥昔单抗和来那度胺治疗,中位随访28.2个月,总缓解率96%、完全缓解率88%,2年无进展生存率76%,安全性可控。

要点

  • 固定疗程epcoritamab联合R2治疗复发/难治性滤泡性淋巴瘤,总缓解率96%、完全缓解率88%。
  • 高危特征患者完全缓解率分别为原发难治90%、抗CD20和烷化剂难治82%、一线治疗24个月内进展83%。
  • 常见治疗中出现的不良事件包括中性粒细胞减少65%、COVID-19 59%和细胞因子释放综合征51%,细胞因子释放综合征多为低级别且均缓解。

核心结论

  • 固定疗程epcoritamab联合R2在复发/难治性滤泡性淋巴瘤中显示出深度、持久的缓解,安全性可控,且不论风险特征如何结局均良好。

研究设计与样本

  • EPCORE NHL-2研究(1b/2期)第2臂,评估固定疗程epcoritamab联合利妥昔单抗和来那度胺(R2)治疗复发/难治性滤泡性淋巴瘤;扩展期108例患者接受至少1剂epcoritamab,中位随访28.2个月。
  • 患者接受epcoritamab(2个递增剂量,之后48 mg全剂量)最多2年,R2最多12个周期(每周期28天)。
  • 主要终点为研究者按Lugano标准评估的总缓解率。

主要发现

  • 总缓解率和完全缓解率分别为96%和88%。
  • 高危特征患者的完全缓解率:原发难治90%,抗CD20和烷化剂难治82%,一线治疗24个月内进展83%。
  • 维持完全缓解、无进展生存、总生存和未开始下一抗淋巴瘤治疗的2年估计值分别为82%、76%、90%和84%。
  • 可评估患者中86%达到微小残留病阴性(clonoSEQ检测)。
  • 常见治疗中出现的不良事件包括中性粒细胞减少65%、COVID-19 59%和细胞因子释放综合征51%;≥3级治疗中出现的不良事件发生于87%的患者,5例发生5级治疗中出现的不良事件(均为COVID-19)。

关键数值与推荐

  • 细胞因子释放综合征事件多为低级别(1级38%、2级11%、3级2%),所有事件均缓解,无一导致epcoritamab停药。
  • 中位年龄65岁;57%的患者既往接受过1线治疗。
  • 截至2024年9月21日的数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2 for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received ≥1 epcoritamab dose in expansion (median follow-up, 28.2 months). Median age was 65 years; 57% had 1 previous line of therapy. ORR and complete response (CR) rate were 96% and 88%, respectively; CR rates in patients with high-risk features were 90% (primary refractory), 82% (refractory to anti-CD20 and an alkylating agent), and 83% (disease progression within 24 months of first-line therapy). Two-year estimates for remaining in CR, progression-free survival, overall survival, and not starting next antilymphoma therapy were 82%, 76%, 90%, and 84%, respectively. Minimal residual disease negativity was observed in 86% of evaluable patients (clonoSEQ assay). Common treatment-emergent adverse events (TEAEs) included neutropenia (65%), COVID-19 (59%), and cytokine release syndrome (CRS; 51%). Grade ≥3 TEAEs occurred in 87% of patients; 5 had grade 5 TEAEs (all COVID-19). CRS events were mostly low grade (grade 1, 38%; grade 2, 11%; grade 3, 2%), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R/R FL, irrespective of risk features. This trial was registered at www.ClinicalTrials.gov as #NCT04663347.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Falchi L, Sureda A, Leppä S, et al. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025. PMID: 40920572. doi:10.1182/blood.2025029909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。